Medpace (NASDAQ:MEDP) Posts Quarterly Earnings Results, Beats Estimates By $0.75 EPS

Medpace (NASDAQ:MEDP) issued its quarterly earnings data on Monday. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75, Briefing.com reports. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same period in the prior year, the business posted $2.27 EPS. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. Medpace updated its FY24 guidance to $10.79-11.47 EPS and its FY 2024 guidance to 10.790-11.470 EPS.

Medpace Trading Up 1.1 %

Shares of NASDAQ:MEDP opened at $376.26 on Tuesday. Medpace has a 52 week low of $187.03 and a 52 week high of $419.42. The company’s 50 day moving average is $396.82 and its two-hundred day moving average is $322.00. The company has a market cap of $11.66 billion, a PE ratio of 42.37, a P/E/G ratio of 1.97 and a beta of 1.38.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 102 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Medpace news, Director Ashley M. Keating sold 250 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total value of $102,467.50. Following the sale, the director now directly owns 250 shares of the company’s stock, valued at approximately $102,467.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 102 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the transaction, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The disclosure for this sale can be found here. In the last three months, insiders have sold 189,340 shares of company stock valued at $76,651,647. Insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent research reports. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and upped their target price for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their target price for the stock from $340.00 to $450.00 in a research note on Tuesday. Finally, Robert W. Baird upped their target price on shares of Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 14th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $395.60.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.